Gilead Sciences climbed 4.4% post-market Thursday as STAT reported severe Covid-19 patients being treated in Chicago with the company’s experimental drug remdesivir are “seeing rapid recoveries in fever and respiratory symptoms.”
Almost all patients were discharged in under than a week, and only two patients died, STAT said, citing comments made this week during a video discussion about trial results with University of Chicago faculty membersSTAT cautions that trials are running at other institutions and full study results can’t yet be determined; Gilead told the news outlet that it’s looking forward to data becoming availableUniversity of Chicago Medicine recruited 125 people into two late-stage studies, including 113 with severe Covid-19Also trading higher post-market are shares of BioCryst Pharmaceuticals, up 8.1%NOTE: The Drugs and Vaccines That Might End the Coronavirus Pandemic.